press release sanofi - Robuta Search

https://www.sanofi.com/en/media-room/press-releases/2026/2026-03-24-06-00-00-3260948 Press Release: Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to... Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoid Approval in moderate-to-severe... press release sanofi dupixent approved first targeted japan medicine https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-17-11-00-00-3239014 Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically... Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the... press release sanofi phase 2b maintenance data demonstrated clinically https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-27-12-03-24-3246438 Press Release: Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic... Sanofi and Regeneron’s Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment If... press release sanofi eu approval treat chronic dupixent recommended https://www.sanofi.com/en/media-room/press-releases/2022/2022-03-31-05-00-00-2413430 Press Release: Sanofi successfully priced an inaugural sustainability-linked bond indexed on access... Sanofi successfully priced an inaugural sustainability-linked bond indexed on access to medicines Paris, March 31, 2022. Sanofi successfully priced yesterday,... press release sanofi sustainability linked successfully priced inaugural https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-10-14-00-56-3235419 Press Release: Sanofi completes the acquisition of Dynavax Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies... press release sanofi completes acquisition dynavax https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-24-14-30-00-3243732 Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine... Sanofi and Regeneron s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6... press release sanofi dupixent approved us first medicine https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-03-06-00-00-3230719 Press Release: Sanofi announces the signing of a share buyback mandate for up to €1 billion Sanofi announces the signing of a share buyback mandate for up to €1 billion Paris, February 3, 2026. On January 29, 2026, Sanofi announced its intention to... press release sanofi share buyback announces signing mandate https://www.sanofi.com/en/media-room/press-releases/2026/2026-04-13-05-00-00-3272182 Press Release: Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to... Sanofi and Regeneron’s Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria Approval in CSU... press release sanofi dupixent approved first targeted eu medicine